Chronic pain patients in the survey reported “greater satisfaction” with cannabis and said that it was “more effective” than their prior therapies.
Archives: News Releases
Since 1992, every Thursday and when breaking news warrants, NORML | The NORML Foundation have been issuing weekly press releases for marijuana law supporters and the media.
NORML’s News Releases archives goes back to 1996 and serves as a valuable tool to alert citizens about cannabis-related news and legislation as well as a research tool for reviewing a chronology of marijuana law reform.
Previous studies have demonstrated that the co-administration of cannabinoids augments the pain-relieving effects of opioids, even when administered at subtherapeutic doses.
Forty-seven percent of respondents reported having authorized cannabis-based therapies to their pediatric patients.
Investigators concluded, “To our knowledge, this is the first longitudinal cohort study … to report an absence of a relationship between cannabis use and risk of AF.”
Researchers “did not find evidence of increases in health service use or incident cases of psychotic disorders over the short-term (17 month) period following cannabis legalization.”
Eighty-eight percent of those surveyed reported that cannabis “reduced their neuropathic pain intensity by more than 30 percent.”
“This is the first population-level prospective study to contribute evidence that medical cannabis is safe for a wide variety of symptoms,” investigators concluded.
#1: More States Enact Adult-Use Marijuana Legalization Laws
Delaware, Minnesota, and Ohio enacted laws in 2023 legalizing adult-use marijuana possession and providing timelines for regulating retail cannabis markets. In addition, Maryland lawmakers passed legislation in May regulating adult-use marijuana sales. Those sales began on July 1st. In January, lawmakers in the US Virgin Islands also approved an adult-use legalization law, though its provisions have yet to take effect.